VerbatimParliament, as it happens

Metachromatic Leukodystrophy

Asked by Gregory StaffordConservativeDepartment of Health and Social CareTabled Answered 1 July 2026UIN 5800

The question

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of adding metachromatic leukodystrophy (MLD) to the NHS newborn blood spot screening programme.

Answered by Mrs Sharon Hodgson

Members of the UK National Screening Committee (UK NSC) have agreed that metachromatic leukodystrophy (MLD) would be a good candidate for the inclusion in a multi-condition in-service evaluation (ISE) within the United Kingdom’s newborn blood spot (NBS) screening programme. The aim of this ISE would be to answer policy-relevant research questions that will allow the UK NSC to make recommendations on adding new conditions to the NBS programme where it is safe to do so.

The UK NSC is using the multi condition ISE in its work with experts and partner organisations to look at how to make it easier to develop the evidence needed to make robust recommendations on adding more rare diseases, such as MLD, to the National Health Service newborn blood spot screening programme.

Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →

Open this question in Verbatim →

Every written question, searchable

155,000 questions tabled since the election, with the answer each department gave — and the ones still unanswered, with the clock running. Free to search.

Search written questions →Read on Verbatim